{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:10:22Z","timestamp":1792887022608,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Molecular tumor boards (MTBs) have become an integral component of precision oncology, yet data on their real-world impact in urologic cancers are limited. This study aimed to characterize the molecular landscape of urologic malignancies presented to the MTB at the University Medical Center Freiburg and to evaluate the frequency and clinical relevance of genomic alterations across tumor entities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 118 patients with histologically confirmed urologic tumors presented at the Freiburg MTB between Januar 2019 and December 2024. Comprehensive molecular profiling was performed using next-generation sequencing (TruSight Oncology 500 or whole exome sequencing). Data were analyzed for mutation frequency, tumor mutational burden (TMB), and co-occurrence patterns, and integrated with clinical data to guide therapy recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Somatic mutations were identified in 90.6% of cases. Frequent alterations included TP53, BRCA2, KMT2D, and ATM, with DNA damage response and chromatin remodeling pathways commonly affected. Prostate cancers showed high rates of BRCA2 and APC co-mutations, indicating potential benefit from combined PARP and Wnt-targeted therapies. In bladder and upper tract urothelial carcinomas (UTUC), KMT2C co-occurred with genes such as SPTA1 and LRP1B, suggesting a hypermutated, immunoresponsive phenotype. Renal tumors frequently harbored alterations in VHL, PBRM1, and SETD2. Rare entities such as penile and testicular tumors displayed distinct mutation patterns, including BRCA1\/2 and MMR gene alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comprehensive molecular profiling in a MTB setting reveals distinct and therapeutically relevant mutational patterns across urologic cancers. These data support the integration of MTBs into clinical workflows and highlight the potential of co-mutational signatures to guide personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1688779","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:13Z","timestamp":1764220393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort"],"prefix":"10.3389","volume":"15","author":[{"given":"Maximilian","family":"Glienke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Zirngibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Miething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Sigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen","family":"Nientiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"B\u00f6rries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Grabbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","volume-title":"Prostate cancer","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.024","article-title":"The emergence of precision urologic oncology: A collaborative review on biomarker-driven therapeutics","volume":"71","author":"Barbieri","year":"2017","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111725","article-title":"Comprehensive outline of whole exome sequencing data analysis tools available in clinical oncology","volume":"11","author":"Bartha","year":"2019","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular tumor boards in clinical practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"B7","volume-title":"TruSight Oncology 500 Reference Guide","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206750","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer","volume":"388","author":"Hussain","year":"2023","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00381-6","article-title":"Niraparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: results from the phase 3 MAGNITUDE study","volume":"23","author":"Chi","year":"2022","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"De Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00529-y","article-title":"Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth","volume":"13","author":"Peng","year":"2024","journal-title":"Oncogenesis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217146","article-title":"ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance","volume":"599","author":"Chen","year":"2024","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237041","article-title":"The role of immunotherapy in MMR-deficient endometrial carcinoma: state of the art and future perspectives","volume":"13","author":"Marchetti","year":"2024","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"B22","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar","year":"2003","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0398","article-title":"Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers","volume":"84","author":"Keller","year":"2024","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2021.1984827","article-title":"KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma","volume":"8","author":"Murugesan","year":"2021","journal-title":"Mol Cell Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1354","article-title":"The metabolic basis of kidney cancer","volume":"9","author":"Linehan","year":"2019","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3886","article-title":"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network","volume":"69","author":"Hakimi","year":"2016","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science (New York N Y)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae220","article-title":"Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study","volume":"30","author":"Monteiro","year":"2025","journal-title":"Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-281","article-title":"Evaluation of NOTCH family genes' expression and prognostic value in prostate cancer","volume":"11","author":"Qing","year":"2022","journal-title":"Trans Androl Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4860367","article-title":"Identifying mutually exclusive gene sets with prognostic value and novel potential driver genes in patients with glioblastoma","volume":"2019","author":"Gao","year":"2019","journal-title":"BioMed Res Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01113","article-title":"Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13839","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat Rev Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-32656-2_16","article-title":"Wnt\/beta-catenin signaling and prostate cancer therapy resistance","volume":"1210","author":"Yeh","year":"2019","journal-title":"Adv Exp Med Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1688779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:14Z","timestamp":1764220394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1688779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":37,"alternative-id":["10.3389\/fonc.2025.1688779"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1688779","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1688779"}}